123 related articles for article (PubMed ID: 12490773)
1. Mirtazapine in the treatment of panic disorder: an open-label trial.
Sarchiapone M; Amore M; De Risio S; Carli V; Faia V; Poterzio F; Balista C; Camardese G; Ferrari G
Int Clin Psychopharmacol; 2003 Jan; 18(1):35-8. PubMed ID: 12490773
[TBL] [Abstract][Full Text] [Related]
2. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period.
Boshuisen ML; Slaap BR; Vester-Blokland ED; den Boer JA
Int Clin Psychopharmacol; 2001 Nov; 16(6):363-8. PubMed ID: 11712626
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine in major depression with comorbid generalized anxiety disorder.
Goodnick PJ; Puig A; DeVane CL; Freund BV
J Clin Psychiatry; 1999 Jul; 60(7):446-8. PubMed ID: 10453798
[TBL] [Abstract][Full Text] [Related]
4. An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis NA; Schweizer E; Rickels K
J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
[TBL] [Abstract][Full Text] [Related]
7. Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.
Slaap BR; Boshuisen ML; van Roon AM; den Boer JA
Int Clin Psychopharmacol; 2002 Mar; 17(2):69-74. PubMed ID: 11892720
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
Guelfi JD; Ansseau M; Timmerman L; Kørsgaard S;
J Clin Psychopharmacol; 2001 Aug; 21(4):425-31. PubMed ID: 11476127
[TBL] [Abstract][Full Text] [Related]
10. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Fawcett J; Barkin RL
J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine compared with paroxetine in major depression.
Benkert O; Szegedi A; Kohnen R
J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Baetz M; Bowen RC
Can J Psychiatry; 1998 Feb; 43(1):73-7. PubMed ID: 9494751
[TBL] [Abstract][Full Text] [Related]
13. Mirtazapine in the treatment of panic disorder.
Carli V; Sarchiapone M; Camardese G; Romano L; DeRisio S
Arch Gen Psychiatry; 2002 Jul; 59(7):661-2. PubMed ID: 12090820
[No Abstract] [Full Text] [Related]
14. Influence of mirtazapine on salivary cortisol in depressed patients.
Laakmann G; Hennig J; Baghai T; Schüle C
Neuropsychobiology; 2003; 47(1):31-6. PubMed ID: 12606843
[TBL] [Abstract][Full Text] [Related]
15. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
Spiegel DA; Saeed SA; Bruce TJ
J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.
Yoon SJ; Pae CU; Kim DJ; Namkoong K; Lee E; Oh DY; Lee YS; Shin DH; Jeong YC; Kim JH; Choi SB; Hwang IB; Shin YC; Cho SN; Lee HK; Lee CT
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1196-201. PubMed ID: 16624467
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages.
Moroz G; Rosenbaum JF
J Clin Psychiatry; 1999 Sep; 60(9):604-12. PubMed ID: 10520979
[TBL] [Abstract][Full Text] [Related]
18. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study.
Saiz-Ruiz J; Montes JM; Ibáñez A; Díaz M; Vicente F; Pelegrín C; Viñas R; Arias F; Carrasco JL; Ferrando L
Hum Psychopharmacol; 2005 Aug; 20(6):435-40. PubMed ID: 16106478
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia.
Poyurovsky M; Bergman J; Pashinian A; Weizman A
Int Clin Psychopharmacol; 2014 Sep; 29(5):296-8. PubMed ID: 24667488
[TBL] [Abstract][Full Text] [Related]
20. Depression does not affect the treatment outcome of CBT for panic and agoraphobia: results from a multicenter randomized trial.
Emmrich A; Beesdo-Baum K; Gloster AT; Knappe S; Höfler M; Arolt V; Deckert J; Gerlach AL; Hamm A; Kircher T; Lang T; Richter J; Ströhle A; Zwanzger P; Wittchen HU
Psychother Psychosom; 2012; 81(3):161-72. PubMed ID: 22399019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
